- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01460524
Nebulized Hypertonic Saline for Bronchiolitis
Observational Study on the Use of Hypertonic Saline for the Treatment of Bronchiolitis
In randomized controlled trials, the use of nebulized hypertonic saline in acute bronchiolitis has been reported to improve respiratory distress scores, to reduce length of hospital stay and to show a trend towards lower hospitalization rates.
The investigators aim to verify by an observational study if the rate of hospital admission and the length of hospital stay of infants presenting to the emergency department (ED) with bronchiolitis decreases after the inclusion of 5.85% nebulized hypertonic saline in the treatment strategy of the ED and hospitalization wards.
The investigators will assess the evolution of hospital admission rates and the length of hospital stay in two hospitals that use 5.85% nebulized hypertonic saline for the treatment of bronchiolitis and in two hospital that do not use these nebulizations. If nebulized hypertonic saline is effective in this setting, then the hospitalization rates and length of stay should be lower during the year of hypertonic saline use compared to two previous years when this therapy was not used. These parameters would not be modified in centers that do not use hypertonic saline.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a before-after observational study designed to compare the results in terms of hospitalization rate and length of hospital stay between a period when nebulized hypertonic saline was included in the treatment of bronchiolitis in infants versus the two previous years when this therapy was not used in two hospitals. There will not be any randomization.
Physicians have been instructed on the use of hypertonic saline for moderate and severe bronchiolitis in infants but its totally up to them whether to use this nebulization for each particular patient. Two other hospital where nebulized hypertonic saline has never been used and will not be used during the next bronchiolitis epidemics will be the control centers.
The study comprises two periods, one prospective starting on November 2011 and ending in March 2012 and one retrospective including the two previous bronchiolitis epidemics, November 2009-March 2012 and November 2010-March 2011.
During the prospective period a standardized assessment of the respiratory status of each infant will be carried out before and after each hypertonic saline nebulization.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Le Chesnay, Frankrike, 78157
- Hopital de Versailles
-
Paris, Frankrike, 75019
- Hôpital Robert Debré
-
Paris, Frankrike, 75012
- Hôpital Armand Trousseau
-
Poissy, Frankrike, 78300
- Chi Poissy Saint Germain En Laye
-
-
Ile-de-France
-
Bondy, Ile-de-France, Frankrike, 93143
- Hôpital Jean Verdier
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- All infants up to 1 year of age presenting to the ED for bronchiolitis during the study periods.
Exclusion Criteria:
- Bronchiolitis in infants older than 1 year
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Hospitalization rate
Tidsram: 6 MONTHS
|
Comparison of hospitalization rates of infants presenting to the ED with bronchiolitis during the year of use of nebulized hypertonic saline versus the two previous years when nebulized hypertonic saline was not used.
|
6 MONTHS
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Length of hospital stay
Tidsram: 6 months
|
Comparison of lenghts of stay of infants hospitalized for bronchiolitis during the year of use of nebulized hypertonic saline in hospitalization wards versus the two previous years when nebulized hypertonic saline was not used.
|
6 months
|
Assessment of 5.85% hypertonic saline tolerance
Tidsram: 6 months
|
A standardized assessment of the respiratory status will be carried out right before and after each nebulization
|
6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Ricardo Carbajal, MD, PhD, Hôpital Armand Trousseau, Paris
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Bronchiolitis-saline
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bronkiolit
-
Rigshospitalet, DenmarkAvslutadStörning relaterad till lungtransplantation | CLAD, Bronchiolitis ObliteransStorbritannien, Belgien, Danmark, Tyskland, Nederländerna, Norge, Sverige
-
University Hospital RegensburgClinAssess GmbHOkändSteroid-refraktär Bronchiolitis ObliteransTyskland
-
Incyte CorporationAktiv, inte rekryterandeKronisk graft kontra värdsjukdom | Myelofibros | Postlungtransplantation (Bronchiolitis Obliterans)Förenta staterna, Spanien, Italien, Tyskland, Belgien, Österrike, Israel, Kanada, Grekland